Article
Neuroprotective implant for treatment of glaucoma in phase II trial
Author(s):
Here's the latest innovations at Neurotech Pharmaceuticals, Inc.
Rich Small, CPA, CEO of Neurotech Pharmaceuticals, Inc., shares what's in the pipeline for retina, glaucoma therapies.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
